

David Jiménez

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4584203/publications.pdf](https://exaly.com/author-pdf/4584203/publications.pdf)

Version: 2024-02-01

267
papers

24,595
citations

38552

50
h-index

7909

151
g-index

283
all docs

283
docs citations

283
times ranked

24448
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2016, 149, 315-352.	0.9	4,169
2	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	2.3	2,735
3	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	2.3	2,642
4	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	5.6	2,484
5	Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2014, 370, 1402-1411.	30.1	1,284
6	Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism. <i>Archives of Internal Medicine</i> , 2010, 170, 1383.	3.7	997
7	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Respiratory Journal</i> , 2019, 54, 1901647.	7.5	890
8	Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019. <i>Chest</i> , 2020, 158, 1143-1163.	0.9	548
9	Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620.	7.0	536
10	Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019. <i>Chest</i> , 2021, 159, 1182-1196.	0.9	383
11	Trends in the Management and Outcomes of Acute Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 162-170.	5.6	287
12	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1536-1544.	5.6	270
13	Predictive Value of the High-Sensitivity Troponin T Assay and the Simplified Pulmonary Embolism Severity Index in Hemodynamically Stable Patients With Acute Pulmonary Embolism. <i>Circulation</i> , 2011, 124, 2716-2724.	9.3	223
14	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	3.5	216
15	Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. <i>European Respiratory Journal</i> , 2014, 44, 694-703.	7.5	198
16	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. <i>Lancet Oncology</i> , The, 2022, 23, e334-e347.	10.8	192
17	Troponin-Based Risk Stratification of Patients With Acute Nonmassive Pulmonary Embolism. <i>Chest</i> , 2009, 136, 974-982.	0.9	183
18	Survival Effects of Inferior Vena Cava Filter in Patients With Acute Symptomatic Venous Thromboembolism and a Significant Bleeding Risk. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1675-1683.	5.6	173

#	ARTICLE	IF	CITATIONS
19	Prognostic Models for Selecting Patients With Acute Pulmonary Embolism for Initial Outpatient Therapy. <i>Chest</i> , 2007, 132, 24-30.	0.9	170
20	Derivation and Validation of Multimarker Prognostication for Normotensive Patients with Acute Symptomatic Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 718-726.	6.6	168
21	Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). <i>Thrombosis and Haemostasis</i> , 2018, 118, 214-224.	3.5	166
22	Prognostic Significance of Deep Vein Thrombosis in Patients Presenting with Acute Symptomatic Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 983-991.	6.6	158
23	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	5.6	155
24	Weekend Versus Weekday Admission and Mortality After Acute Pulmonary Embolism. <i>Circulation</i> , 2009, 119, 962-968.	9.3	154
25	Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. <i>European Respiratory Journal</i> , 2014, 43, 1669-1677.	7.5	127
26	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-2018: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021, 9, 33-42.	10.4	122
27	Incidence of Air Travel-Related Pulmonary Embolism at the Madrid-Barajas Airport. <i>Archives of Internal Medicine</i> , 2003, 163, 2766.	3.7	120
28	Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. <i>Thorax</i> , 2011, 66, 75-81.	7.2	116
29	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	2.3	116
30	Home treatment in pulmonary embolism. <i>Thrombosis Research</i> , 2010, 126, e1-e5.	1.7	113
31	Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 110, 834-843.	3.5	95
32	Trends in hospital admissions for pulmonary embolism in Spain from 2002 to 2011. <i>European Respiratory Journal</i> , 2014, 44, 942-950.	7.5	94
33	Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2015, 148, 211-218.	0.9	89
34	Risk Stratification of Patients With Acute Symptomatic Pulmonary Embolism Based on Presence or Absence of Lower Extremity DVT. <i>Chest</i> , 2016, 149, 192-200.	0.9	78
35	A Strategy Combining Imaging and Laboratory Biomarkers in Comparison With a Simplified Clinical Score for Risk Stratification of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2012, 141, 916-922.	0.9	77
36	Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 574.	7.0	75

#	ARTICLE	IF	CITATIONS
37	Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. <i>European Heart Journal</i> , 2021, 42, 3146-3157.	2.3	75
38	Risk stratification of normotensive patients with acute symptomatic pulmonary embolism. <i>British Journal of Haematology</i> , 2010, 151, 415-424.	2.7	72
39	Prognostic Significance of Right Heart Thrombi in Patients With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2017, 151, 409-416.	0.9	71
40	Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar. <i>Archivos De Bronconeumología</i> , 2013, 49, 534-547.	1.0	70
41	Pulmonary Embolism in Patients with Chronic Obstructive Pulmonary Disease or Congestive Heart Failure. <i>American Journal of Medicine</i> , 2006, 119, 851-858.	1.4	69
42	Thromboprophylaxis in Patients With COVID-19. <i>Chest</i> , 2022, 162, 213-225.	0.9	67
43	Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020, 196, 382-394.	1.7	65
44	Right heart thrombi in pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 48, 1377-1385.	7.5	64
45	Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. <i>Thorax</i> , 2015, 70, 333-338.	7.2	63
46	Prognostic significance of multidetector CT in normotensive patients with pulmonary embolism: results of the protect study. <i>Thorax</i> , 2014, 69, 109-115.	7.2	62
47	Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141.	3.5	60
48	A Clinical Prognostic Model for the Identification of Low-Risk Patients With Acute Symptomatic Pulmonary Embolism and Active Cancer. <i>Chest</i> , 2013, 143, 138-145.	0.9	59
49	Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, 4186-4195.	2.3	58
50	Short-term clinical outcome after acute symptomatic pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2008, 100, 937-942.	3.5	56
51	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. <i>Chest</i> , 2017, 151, 564-571.	0.9	54
52	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 982-991.	3.5	54
53	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. <i>Human Molecular Genetics</i> , 2022, 31, 3945-3966.	3.0	54
54	A comparison of the original and simplified Pulmonary Embolism Severity Index. <i>Thrombosis and Haemostasis</i> , 2011, 106, 423-428.	3.5	53

#	ARTICLE	IF	CITATIONS
55	Escala de riesgo de eventos adversos a corto plazo en pacientes con tromboembolia pulmonar. Archivos De Bronconeumología, 2007, 43, 617-622.	1.0	52
56	Reduced-Dose Intravenous Thrombolysis for Acute Intermediate- to High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International Thrombolysis (PEITHO)-3 trial. Thrombosis and Haemostasis, 2022, 122, 857-866.	3.5	51
57	Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Current Opinion in Pulmonary Medicine, 2008, 14, 414-421.	2.7	47
58	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. American Journal of Medicine, 2017, 130, 588-595.	1.4	47
59	Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism. Thrombosis Research, 2011, 127, 303-308.	1.7	46
60	Epidemiology, patterns of care and mortality for patients with hemodynamically unstable acute symptomatic pulmonary embolism. International Journal of Cardiology, 2018, 269, 327-333.	1.6	45
61	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clinical Research in Cardiology, 2019, 108, 772-778.	3.5	45
62	Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis. European Heart Journal, 2021, 42, 3190-3199.	2.3	44
63	Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. Journal of the American College of Cardiology, 2021, 78, 408-411.	5.6	44
64	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. Journal of the American College of Cardiology, 2021, 78, 1635-1654.	5.6	43
65	Risk stratification of patients with acute symptomatic pulmonary embolism. Internal and Emergency Medicine, 2016, 11, 11-18.	2.2	42
66	Sex differences in the characteristics and short-term prognosis of patients presenting with acute symptomatic pulmonary embolism. PLoS ONE, 2017, 12, e0187648.	2.5	42
67	Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ: British Medical Journal, 2019, 366, l4416.	5.6	42
68	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Quality of Life Research, 2019, 28, 2111-2124.	3.2	42
69	Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2021, 19, 1981-1989.	4.1	42
70	Incidence of Symptomatic and Asymptomatic Chronic Thromboembolic Pulmonary Hypertension. Archivos De Bronconeumología, 2010, 46, 628-633.	1.0	41
71	Interobserver reliability of echocardiography for prognostication of normotensive patients with pulmonary embolism. Cardiovascular Ultrasound, 2014, 12, 29.	1.6	40
72	Meta-Analysis of Prevalence and Short-Term Prognosis of Hemodynamically Unstable Patients With Symptomatic Acute Pulmonary Embolism. American Journal of Cardiology, 2019, 123, 684-689.	1.6	39

#	ARTICLE	IF	CITATIONS
73	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, 191-197.	3.5	38
74	Prognostic value of right ventricular dilatation in patients with low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2017, 50, 1701611.	7.5	38
75	Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: systematic review and network meta-analysis. <i>Thorax</i> , 2018, 73, 464-471.	7.2	38
76	Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism. <i>European Respiratory Journal</i> , 2015, 45, 1323-1331.	7.5	37
77	Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2440-2448.	3.6	36
78	Comparison of clinical scores for identification of patients with pulmonary embolism at intermediateâ€“high risk of adverse clinical outcome: the prognostic role of plasma lactate. <i>Internal and Emergency Medicine</i> , 2017, 12, 657-665.	2.2	36
79	A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism. <i>Thrombosis Research</i> , 2018, 165, 107-111.	1.7	36
80	Presenting Characteristics, Treatment Patterns, and Outcomes among Patients with Venous Thromboembolism during Hospitalization for COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 351-361.	2.7	36
81	Changes in PESI scores predict mortality in intermediate-risk patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2013, 41, 354-359.	7.5	34
82	Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study. <i>European Respiratory Journal</i> , 2018, 51, 1702037.	7.5	34
83	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009042.	3.9	34
84	Management appropriateness and outcomes of patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2018, 51, 1800445.	7.5	34
85	Obstructive sleep apnoea and venous thromboembolism: pathophysiological links and clinical implications. <i>European Respiratory Journal</i> , 2019, 53, 1800893.	7.5	34
86	Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. <i>European Respiratory Journal</i> , 2020, 56, 2002336.	7.5	33
87	Prognostic significance of multidetector computed tomography in normotensive patients with pulmonary embolism: rationale, methodology and reproducibility for the PROTECT study. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 187-192.	2.2	32
88	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1277.	7.0	32
89	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELDâ€“VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.	4.1	31
90	Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. <i>Thrombosis and Haemostasis</i> , 2016, 115, 827-834.	3.5	30

#	ARTICLE	IF	CITATIONS
91	Assessment of right ventricular function in acute pulmonary embolism. <i>American Heart Journal</i> , 2017, 185, 123-129.	3.1	30
92	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. <i>Thrombosis Research</i> , 2018, 170, 181-191.	1.7	29
93	Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy. <i>Annals of the American Thoracic Society</i> , 2015, 12, 150626095350002.	3.6	28
94	A Clinical Prediction Rule for Identifying Short-Term Risk of Adverse Events in Patients With Pulmonary Thromboembolism. <i>Archivos De Bronconeumologia</i> , 2007, 43, 617-622.	1.0	27
95	Valor pronóstico de los hallazgos electrocardiográficos en pacientes estables hemodinámicamente con tromboembolia de pulmón aguda sintomática. <i>Revista Espanola De Cardiologia</i> , 2008, 61, 244-250.	1.4	26
96	Apixaban: an Oral Direct Factor-Xa Inhibitor. <i>Advances in Therapy</i> , 2012, 29, 187-201.	3.0	26
97	The Prognostic Value of Renal Function in Acute Pulmonary Embolism—A Multi-Centre Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 140-148.	3.5	26
98	Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding. <i>Academic Emergency Medicine</i> , 2016, 23, 144-150.	1.9	25
99	DVT Management and Outcome Trends, 2001 to 2014. <i>Chest</i> , 2016, 150, 374-383.	0.9	24
100	Catheter-directed aspiration thrombectomy and low-dose thrombolysis for patients with acute unstable pulmonary embolism: Prospective outcomes from a PE registry. <i>International Journal of Cardiology</i> , 2019, 287, 106-110.	1.6	24
101	Intermediate-High Risk Pulmonary Embolism. <i>TH Open</i> , 2019, 03, e356-e363.	1.5	24
102	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2022, 161, 524-534.	0.9	22
103	Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. <i>JAMA Cardiology</i> , 2022, 7, 857.	6.5	22
104	Association of anaemia and mortality in patients with acute pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2009, 102, 153-158.	3.5	21
105	Identification of Reduced Circulating Haptoglobin Concentration as a Biomarker of the Severity of Pulmonary Embolism: A Nontargeted Proteomic Study. <i>PLoS ONE</i> , 2014, 9, e100902.	2.5	21
106	Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. <i>European Respiratory Journal</i> , 2016, 48, 1360-1368.	7.5	21
107	Clinical Prognosis of Nonmassive Central and Noncentral Pulmonary Embolism. <i>Chest</i> , 2017, 151, 829-837.	0.9	21
108	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	6.5	21

#	ARTICLE	IF	CITATIONS
109	Pulmonary embolism response teams: Changing the paradigm in the care for acute pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2457-2464.	4.1	21
110	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	7.5	19
111	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. <i>PLoS ONE</i> , 2018, 13, e0194673.	2.5	18
112	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. <i>Viruses</i> , 2022, 14, 178.	3.4	18
113	Prognostic importance of anaemia in patients with acute pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2011, 106, 289-295.	3.5	16
114	Controversies in the Management of Life-Threatening Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 835-841.	2.2	16
115	Type 2 diabetes is associated with a higher incidence of hospitalization for pulmonary embolism in Spain: Analysis of hospital discharge data during 2004–2013. <i>Respirology</i> , 2016, 21, 1277-1284.	2.9	16
116	Accuracy and Interobserver Reliability of the Simplified Pulmonary Embolism Severity Index Versus the Hestia Criteria for Patients With Pulmonary Embolism. <i>Academic Emergency Medicine</i> , 2019, 26, 394-401.	1.9	16
117	Systolic blood pressure and mortality in acute symptomatic pulmonary embolism. <i>International Journal of Cardiology</i> , 2020, 302, 157-163.	1.6	16
118	Consenso multidisciplinar para el manejo de la tromboembolia de pulmón. <i>Archivos De Bronconeumología</i> , 2022, 58, 246-254.	1.0	16
119	Impact of obstructive sleep apnea on cardiovascular outcomes in patients with acute symptomatic pulmonary embolism: Rationale and methodology for the POPE study. <i>Clinical Cardiology</i> , 2017, 40, 1182-1188.	1.9	15
120	Design and rationale of the non-interventional, edoxaban treatment in routine clinical practice in patients with venous thromboembolism in Europe (ETNA-VTE-Europe) study. <i>Thrombosis Journal</i> , 2018, 16, 9.	2.1	15
121	Enfermedad pulmonar obstructiva crónica en pacientes con tromboembolia de pulmón aguda sintomática. <i>Archivos De Bronconeumología</i> , 2009, 45, 286-290.	1.0	14
122	Chronic Obstructive Pulmonary Disease in Patients With Acute Symptomatic Pulmonary Embolism. <i>Archivos De Bronconeumología</i> , 2009, 45, 286-290.	1.0	14
123	Point: Should Systemic Lytic Therapy Be Used for Submassive Pulmonary Embolism? Yes. <i>Chest</i> , 2013, 143, 296-299.	0.9	14
124	Risk stratification of acute pulmonary embolism based on clinical parameters, H-FABP and multidetector CT. <i>International Journal of Cardiology</i> , 2018, 265, 223-228.	1.6	14
125	Pulmonary embolism severity assessment and prognostication. <i>Thrombosis Research</i> , 2018, 163, 246-251.	1.7	14
126	Renal dysfunction improves risk stratification and may call for a change in the management of intermediate- and high-risk acute pulmonary embolism: results from a multicenter cohort study with external validation. <i>Critical Care</i> , 2021, 25, 57.	6.0	14

#	ARTICLE	IF	CITATIONS
127	Prognostic Impact of Obstructive Sleep Apnea in Patients Presenting with Acute Symptomatic Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , 2021, 121, 808-815.	3.5	14
128	Assessment of coexisting deep vein thrombosis for risk stratification of acute pulmonary embolism. <i>Thrombosis Research</i> , 2018, 164, 40-44.	1.7	13
129	Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2019, 45, 793-801.	2.7	13
130	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. <i>European Respiratory Journal</i> , 2019, 53, 1801677.	7.5	13
131	Riesgo trombótico y COVID-19: revisión de la evidencia actual para una mejor aproximación diagnóstica y terapéutica. <i>Archivos De Bronconeumología</i> , 2021, 57, 55-64.	1.0	13
132	Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2022, 59, 2100412.	7.5	13
133	Validación de 2 escalas clínicas pronósticas en pacientes con tromboembolia pulmonar aguda sintomática. <i>Archivos De Bronconeumología</i> , 2013, 49, 427-431.	1.0	12
134	Risk Stratification for Proven Acute Pulmonary Embolism: What Information Is Needed?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 011-017.	2.2	12
135	Outcomes after Vena Cava Filter Use in Patients with Cancer-Associated Venous Thromboembolism and Contraindications to Anticoagulation. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1035-1044.	3.5	12
136	Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 408-416.	4.1	12
137	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> , 2021, 8, e627-e636.	4.6	12
138	Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 58, 2002723.	7.5	12
139	Valor pronóstico de la ecocardiografía transtorácica en pacientes estables hemodinámicamente con tromboembolia de pulmón aguda sintomática. <i>Archivos De Bronconeumología</i> , 2007, 43, 490-494.	1.0	11
140	Validation of Two Clinical Prognostic Models in Patients With Acute Symptomatic Pulmonary Embolism. <i>Archivos De Bronconeumología</i> , 2013, 49, 427-431.	1.0	11
141	Pulmonary embolism: current and new treatment options. <i>Current Medical Research and Opinion</i> , 2014, 30, 1975-1989.	2.0	11
142	Pulmonary embolism, acute coronary syndrome and ischemic stroke in the Spanish National Discharge Database. <i>European Journal of Internal Medicine</i> , 2016, 28, 65-69.	2.3	11
143	Catheter-Based Approaches for the Treatment of Acute Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 073-083.	2.2	11
144	Evaluación clínica frente a escalas estandarizadas para el pronóstico de los pacientes con tromboembolia pulmonar aguda sintomática. <i>Medicina Clínica</i> , 2018, 151, 136-140.	0.6	11

#	ARTICLE	IF	CITATIONS
145	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. <i>Clinical Cardiology</i> , 2019, 42, 346-351.	1.9	11
146	Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , 2019, 179, 263.	5.1	11
147	Systematic review of efficacy and safety of retrievable inferior vena caval filters. <i>Thrombosis Research</i> , 2018, 165, 79-82.	1.7	10
148	Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days. <i>American Heart Journal</i> , 2018, 206, 1-10.	3.1	10
149	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2019, 14, 1101-1112.	2.2	10
150	Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 168-178.	2.4	10
151	Revised Paradigm for Acute Pulmonary Embolism Prognostication and Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 208, 524-527.	6.6	10
152	National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism. <i>Archivos De Bronconeumologia</i> , 2013, 49, 534-547.	1.0	9
153	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2425-2434.	3.5	9
154	Aggressive Treatment of Intermediate-Risk Patients with Acute Symptomatic Pulmonary Embolism. <i>Clinics in Chest Medicine</i> , 2018, 39, 569-581.	2.2	9
155	Pulmonary Embolism Response Teams: Pursuing Excellence in the Care for Venous Thromboembolism. <i>Archives of Medical Research</i> , 2019, 50, 257-258.	3.5	9
156	Changing Trends in Hospital Admissions for Pulmonary Embolism in Spain from 2001 to 2018. <i>Journal of Clinical Medicine</i> , 2020, 9, 3221.	2.5	9
157	Association between reperfusion therapy and outcomes in patients with acute pulmonary embolism and right heart thrombi. <i>European Respiratory Journal</i> , 2020, 56, 2000538.	7.5	9
158	Recomendaciones SEPAR sobre la vacuna COVID-19 en las enfermedades respiratorias. <i>Open Respiratory Archives</i> , 2021, 3, 100097.	0.3	9
159	Systematic testing for venous thromboembolism in hospitalized patients with COVID-19 and raised D-dimer levels. <i>Thrombosis Update</i> , 2021, 2, 100029.	0.9	9
160	Risk assessment and management of high and intermediate risk pulmonary embolism. <i>Presse Medicale</i> , 2015, 44, e401-e408.	2.1	8
161	Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010651.	2.7	8
162	Clinical conundrum: concomitant high-risk pulmonary embolism and acute ischemic stroke. <i>Emergency Radiology</i> , 2020, 27, 433-439.	1.9	8

#	ARTICLE	IF	CITATIONS
163	The effect of COPD on the incidence and mortality of hospitalized patients with pulmonary embolism: A nationwide population-based study (2016-2018). <i>European Journal of Internal Medicine</i> , 2021, 84, 18-23.	2.3	8
164	Pulmonary Embolism in Patients with COVID-19: Comparison between Different Care Settings. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 034-046.	2.7	8
165	Prognostic Scores for Acute Pulmonary Embolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 486-492.	2.7	7
166	Diclofenac for reversal of right ventricular dysfunction in acute normotensive pulmonary embolism: A pilot study. <i>Thrombosis Research</i> , 2018, 162, 1-6.	1.7	7
167	Comparison of All-Cause Mortality Following VTE Treatment Between Propensity Score-Adjusted Observational Studies and Matched Randomized Controlled Trials. <i>Chest</i> , 2019, 155, 689-698.	0.9	7
168	Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 769.	2.4	7
169	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. <i>Viruses</i> , 2021, 13, 2128.	3.4	7
170	Untreated obstructive sleep apnea and cardiovascular outcomes in patients with acute symptomatic pulmonary embolism. <i>Thrombosis Research</i> , 2022, 214, 87-92.	1.7	7
171	Prognostic Value of Transthoracic Echocardiography in Hemodynamically Stable Patients With Acute Symptomatic Pulmonary Embolism. <i>Archivos De Bronconeumologia</i> , 2007, 43, 490-494.	1.0	6
172	Factores de riesgo de la hipertensi3n pulmonar tromboemb3lica cr3nica. <i>Archivos De Bronconeumologia</i> , 2009, 45, 11-14.	1.0	6
173	Performance of Early Prognostic Assessment Independently Predicts the Outcomes in Patients with Acute Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , 2018, 47, 798-800.	3.5	6
174	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 489-495.	1.7	6
175	Success in Optional Vena Cava Filter Retrieval. An Analysis of 246 Patients. <i>Archivos De Bronconeumologia</i> , 2018, 54, 371-377.	1.0	6
176	Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. <i>Scientific Reports</i> , 2019, 9, 20064.	3.4	6
177	Prognostic significance of computed tomography-assessed right ventricular enlargement in low-risk patients with pulmonary embolism: Systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021, 197, 48-55.	1.7	6
178	Risk stratification for predicting recurrent venous thromboembolism after discontinuation of anticoagulation: a post hoc analysis of a French prospective multicentre study. <i>European Respiratory Journal</i> , 2022, 60, 2103002.	7.5	6
179	COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. <i>Chest</i> , 2022, 161, 1448-1451.	0.9	6
180	[Translated article] Multidisciplinary consensus for the management of pulmonary thromboembolism. <i>Archivos De Bronconeumologia</i> , 2022, 58, T246-T254.	1.0	6

#	ARTICLE	IF	CITATIONS
181	Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1839-1851.	4.1	6
182	Complicaciones precoces en pacientes con embolia de pulmón. <i>Medicina Clínica</i> , 2006, 127, 1-4.	0.6	5
183	Pulmonary embolism in Europe remains a cause of concern despite declining deaths. <i>Lancet Respiratory Medicine</i> , 2020, 8, 222-224.	10.4	5
184	Atrial fibrillation in the course of pulmonary embolism: just a little smoke, or fuel to the fire?. <i>Journal of Internal Medicine</i> , 2020, 287, 114-116.	6.2	5
185	Necesidad de una ecocardiografía transtorácica en pacientes con tromboembolia de pulmón de riesgo bajo: revisión sistemática y metanálisis. <i>Archivos De Bronconeumología</i> , 2020, 56, 306-313.	1.0	5
186	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. <i>European Journal of Internal Medicine</i> , 2020, 82, 48-55.	2.3	5
187	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. <i>Thrombosis Research</i> , 2020, 196, 297-304.	1.7	5
188	Need for Transthoracic Echocardiogram in Patients with Low-Risk Pulmonary Thromboembolism: A Systematic Review and Meta-Analysis. <i>Archivos De Bronconeumología</i> , 2020, 56, 306-313.	1.0	5
189	RIETE Registry: Past, Present and Future. <i>Archivos De Bronconeumología</i> , 2022, 58, 205-207.	1.0	5
190	The significance of heart failure in hospitalised patients with pulmonary embolism. A gender-specific analysis. <i>International Journal of Clinical Practice</i> , 2021, 75, e14558.	1.7	5
191	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.	3.9	5
192	Developing Validated Tools to Identify Pulmonary Embolism in Electronic Databases: Rationale and Design of the PE-EHR+ Study. <i>Thrombosis and Haemostasis</i> , 2023, 123, 649-662.	3.5	5
193	Clinical significance and management of right heart thrombi: more questions than answers. <i>European Respiratory Journal</i> , 2016, 47, 702-703.	7.5	4
194	Actualización del Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia de pulmón. <i>Archivos De Bronconeumología</i> , 2016, 52, 61-62.	1.0	4
195	Éxito en la recuperación de filtro de vena cava inferior opcional: Análisis de 246 pacientes. <i>Archivos De Bronconeumología</i> , 2018, 54, 371-377.	1.0	4
196	Impact and Role of Pulmonary Embolism Response Teams in Venous Thromboembolism Associated with Covid-19. <i>Journal of Investigative Medicine</i> , 2021, 69, 1153-1155.	1.8	4
197	Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 58-66.	2.2	4
198	Sex Differences in Presentation, Risk Factors, Drug and Interventional Therapies, and Outcomes of Elderly Patients with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	1.7	4

#	ARTICLE	IF	CITATIONS
199	Clinical Characteristics and Prognosis of Pulmonary Embolism Caused by Economy Class Syndrome. Archivos De Bronconeumologia, 2017, 53, 495-500.	1.0	3
200	Outpatient therapy for acute symptomatic pulmonary embolism diagnosed in the emergency department: Time to improve the evidence base. Thrombosis Research, 2018, 161, 117-118.	1.7	3
201	Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism. TH Open, 2018, 02, e428-e436.	1.5	3
202	Risk adapted management of acute pulmonary embolism in women. Thrombosis Research, 2019, 181, S29-S32.	1.7	3
203	Outcome of patients with acute symptomatic pulmonary embolism and psychiatric disorders. Thrombosis Research, 2020, 193, 90-97.	1.7	3
204	Imaging modalities for confirming pulmonary embolism during pregnancy: results from a multicenter international study. European Radiology, 2022, 32, 1238-1246.	4.6	3
205	Sex-differences in the effect of obstructive sleep apnea on patients hospitalized with pulmonary embolism and on in-hospital mortality. Scientific Reports, 2021, 11, 18390.	3.4	3
206	Association between obstructive sleep apnea and venous thromboembolism recurrence: results from a French cohort. Thrombosis Journal, 2022, 20, 1.	2.1	3
207	Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial. Thrombosis Journal, 2022, 20, 10.	2.1	3
208	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. Contemporary Clinical Trials, 2022, 115, 106714.	1.9	3
209	Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial. Thrombosis and Haemostasis, 2023, 123, 723-733.	3.5	3
210	Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism. Chest, 2024, 165, 673-681.	0.9	3
211	A propósito de: ¿Puede reducir la mortalidad de los pacientes con EPOC la profilaxis domiciliaria de la enfermedad tromboembólica venosa? Archivos De Bronconeumologia, 2007, 43, 523-524.	1.0	2
212	Early discharge and outpatient treatment of patients admitted for acute pulmonary embolism. European Respiratory Journal, 2013, 41, 487-488.	7.5	2
213	Outpatient Management Eligibility Criteria for Patients Who Have Acute Symptomatic Pulmonary Embolism. Annals of the American Thoracic Society, 2015, 12, 623-624.	3.6	2
214	Cardiopulmonary exercise testing with ventilatory gas analysis for evaluation of chronic thromboembolic pulmonary hypertension: Unmasking its role after a therapeutic intervention. International Journal of Cardiology, 2019, 296, 155-156.	1.6	2
215	Hemopericardium and Cardiac Tamponade as a Complication of Vena Caval Filters: Systematic Review of the Published Literature and the MAUDE Database. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961984911.	1.7	2
216	Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. Thrombosis Research, 2020, 186, 78-79.	1.7	2

#	ARTICLE	IF	CITATIONS
217	Safety of Apixaban for Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 547-551.	3.5	2
218	Implications of Abnormal Troponin Levels With Normal Right Ventricular Function in Normotensive Patients With Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096776.	1.7	2
219	Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism. <i>Blood</i> , 2019, 134, 2429-2429.	1.4	2
220	Participación de los equipos de respuesta rápida de tromboembolia pulmonar durante el perioperatorio. <i>Archivos De Cardiología De Mexico</i> , 2020, 90, 321-327.	0.2	2
221	Comparison of Full-Dose vs Moderate-Dose Systemic Thrombolysis for the Treatment of Patients With Acute Pulmonary Embolism. <i>Chest</i> , 2022, 162, 448-451.	0.9	2
222	A Comparison of GFR Calculated by Cockcroft-Gault vs. MDRD Formula in the Prognostic Assessment of Patients with Acute Pulmonary Embolism. <i>Disease Markers</i> , 2021, 2021, 1-9.	1.4	2
223	Ibero-American Society of Interventionism (SIDI) and the Spanish Society of Vascular and Interventional Radiology (SERVEI) Standard of Practice (SOP) for the Management of Inferior Vena Cava Filters in the Treatment of Acute Venous Thromboembolism. <i>Journal of Clinical Medicine</i> , 2022, 11, 77.	2.5	2
224	Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 872115.	2.5	2
225	The rationale, design, and methods of a trial to evaluate the efficacy and safety of oxygen therapy in patients with intermediate-risk acute pulmonary embolism. <i>American Heart Journal</i> , 2023, 257, 62-68.	3.1	2
226	Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade. <i>Cancers</i> , 2024, 16, 450.	3.8	2
227	Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. <i>Nature Reviews Cardiology</i> , 0, , .	13.8	2
228	Prognostication of Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1096-1097.	6.6	1
229	Análisis coste-efectividad de rivaroxabán en el tratamiento del tromboembolismo venoso en España. <i>Pharmacoeconomics - Spanish Research Articles</i> , 2015, 12, 147-156.	0.1	1
230	Características clínicas y pronóstico de la tromboembolia pulmonar secundaria al síndrome de clase turista. <i>Archivos De Bronconeumología</i> , 2017, 53, 495-500.	1.0	1
231	Surrogate Endpoints for Pulmonary Hypertension Management and Trial Design. <i>Journal of the American College of Cardiology</i> , 2018, 71, 764-765.	5.6	1
232	Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos. <i>Archivos De Bronconeumología</i> , 2018, 54, 359-360.	1.0	1
233	Clinical gestalt versus prognostic scores for prognostication of patients with acute symptomatic pulmonary embolism. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 136-140.	0.2	1
234	Scores to Identify Occult Cancer in Venous Thromboembolism: Do They Work?. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1343-1344.	3.5	1

#	ARTICLE	IF	CITATIONS
235	The Role of the Pulmonologist in a Pulmonary Embolism Response Team (PERT): A Time to Come on Stage. Archivos De Bronconeumologia, 2019, 55, 1-2.	1.0	1
236	Assembly 13: placing the pulmonary circulation in the heart of ERS. Breathe, 2019, 15, 88-89.	1.4	1
237	The Role of the Pulmonologist in a Pulmonary Embolism Response Team (PERT): A Time to Come on Stage. Archivos De Bronconeumologia, 2019, 55, 1-2.	1.0	1
238	Duration of anticoagulant therapy after pulmonary embolism can be a tough decision. Archivos De Bronconeumologia, 2020, 56, 617-618.	1.0	1
239	Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093120.	1.7	1
240	Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism. The Cochrane Library, 0, , .	2.8	1
241	Refinement of a modified simplified Pulmonary Embolism Severity Index for elderly patients with acute pulmonary embolism. International Journal of Cardiology, 2021, 335, 111-117.	1.6	1
242	Respuesta a "Consenso multidisciplinar, ¿falta alguien?". Archivos De Bronconeumologia, 2021, 57, 612.	1.0	1
243	Comentarios a la guía ESC 2019 sobre embolia pulmonar aguda. Revista Espanola De Cardiologia, 2020, 73, 452-456.	1.4	1
244	[Translated article] Prognostic Significance of Findings on CTPA Supporting an Alternative Diagnosis to PE Among Patients Hospitalized for an Exacerbation of COPD: Predefined Subanalysis of the SLICE Trial. Archivos De Bronconeumologia, 2022, 58, T412-T417.	1.0	1
245	The $\hat{\mu}^2$ $\hat{\mu}^2$ -Encoders for Robust A/D Conversion. Acta Applicandae Mathematicae, 2009, 107, 313-323.	1.0	0
246	Mortality-Risk Profiling using Doppler Leg Scans in Patients with Pulmonary Embolism. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 856-857.	6.6	0
247	Rebuttal From Dr Jiméñez. Chest, 2013, 143, 302-303.	0.9	0
248	Prognostic Scores in Pulmonary Embolism: Response. Chest, 2013, 143, 873.	0.9	0
249	Hipertensión pulmonar tromboembólica crónica: la experiencia mejora los resultados. Archivos De Bronconeumologia, 2014, 50, 507-508.	1.0	0
250	National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism: An Update. Archivos De Bronconeumologia, 2016, 52, 61-62.	1.0	0
251	Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians. Archivos De Bronconeumologia, 2018, 54, 359-360.	1.0	0
252	Highlights from the ERS International Congress 2018: Assembly 13 "Pulmonary Vascular Diseases. ERJ Open Research, 2019, 5, 00202-2018.	2.7	0

#	ARTICLE	IF	CITATIONS
253	Duración de la anticoagulación tras una tromboembolia de pulmón: una decisión no siempre sencilla. Archivos De Bronconeumología, 2020, 56, 617-618.	1.0	0
254	Spanish consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumología, 2021, 57, 612.	1.0	0
255	Cardiovascular mortality and morbidity in pulmonary embolism. , 2020, , 184-197.		0
256	A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation—Reply. JAMA - Journal of the American Medical Association, 2022, 327, 184.	7.0	0
257	Major bleeding in patients with pulmonary embolism presenting with syncope. European Journal of Clinical Investigation, 2022, , e13774.	3.4	0
258	Significado pronóstico de los diagnósticos alternativos a la TEP hallados en la tomografía computarizada de tórax de pacientes ingresados por agudización de EPOC: subanálisis predefinido del ensayo SLICE. Archivos De Bronconeumología, 2022, , .	1.0	0
259	Rebuttal From Dr David Jimenez et al. Chest, 2022, 161, 1453-1455.	0.9	0
260	—Pulmonary embolism response teams: changing the paradigm in the care for acute pulmonary embolism—reply. Journal of Thrombosis and Haemostasis, 2023, 21, 1390-1392.	4.1	0
261	La especialidad de Neumología. Antecedentes. Desarrollo asistencial y científico. Perspectivas futuras. Revista De Investigación Y Educación En Ciencias De La Salud (RIECS), 2023, 8, 17-24.	0.1	0
262	Validation of Echocardiographic Measurements in Patients with Pulmonary Embolism in the RIETE Registry. TH Open, 2024, 08, e1-e8.	1.5	0
263	Pulmonary embolism: Put the sPESI into practice. European Journal of Internal Medicine, 2024, 124, 40-41.	2.3	0
264	Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study. EClinicalMedicine, 2024, 73, 102659.	7.2	0
265	Response. Chest, 2024, 166, e100.	0.9	0
266	Predictors of pulmonary embolism in chronic obstructive pulmonary diseases patients admitted for worsening respiratory symptoms: An individual participant data meta-analyses. European Journal of Internal Medicine, 2024, , .	2.3	0
267	International Clinical Practice Guideline—Recommendations for Acute—Pulmonary Embolism. Journal of the American College of Cardiology, 2024, 84, 1561-1577.	5.6	0